A Phase 1/2 interventional study of Elacestrant and Onapristone in Breast Cancer, sponsored by Context Therapeutics Inc.. Withdrawn at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-22.
Sponsored by Context Therapeutics Inc. · Phase 1/2, Interventional, and Treatment
This is a rollover study for patients enrolled in the discontinued ELONA clinical trial (ONA-XR-103) with the primary objective to characterize the safety of elacestrant in combination with onapristone either alone or in combination.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
Browse Breast Neoplasms studies →Context Therapeutics Inc. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Elacestrant and Onapristone combination
Drug: Elacestrant · Drug: Onapristone
Elacestrant 200mg once daily oral dosing in cycles of 28 days.
Also known as: RAD1901
Onapristone 40mg twice daily oral dosing in cycles of 28 days.
Characterize the safety of elacestrant in combination with onapristone.
Monitor the treatment-related adverse events as assessed by CTCAE v4.0
Time frame: 7 months
This study is withdrawn, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Context Therapeutics Inc.